Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
0.2503
-0.0003 (-0.12%)
At close: Apr 11, 2025, 4:00 PM
0.2515
+0.0012 (0.49%)
After-hours: Apr 11, 2025, 7:56 PM EDT
Rallybio Revenue
In the year 2024, Rallybio had annual revenue of $636.00K. Rallybio had revenue of $38.00K in the quarter ending December 31, 2024.
Revenue (ttm)
$636.00K
Revenue Growth
n/a
P/S Ratio
17.14
Revenue / Employee
$25,440
Employees
25
Market Cap
10.42M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
RLYB News
- 5 days ago - Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints - Benzinga
- 5 days ago - Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT - Business Wire
- 4 weeks ago - Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - Business Wire
- 6 weeks ago - Rallybio to Present at the TD Cowen 45th Annual Health Care Conference - Business Wire
- 2 months ago - Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial - Business Wire
- 3 months ago - Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025 - Business Wire
- 4 months ago - Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting - Business Wire
- 4 months ago - Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025 - Business Wire